Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biomet Begins Ceramic Hip Implant Study, As Stryker Nears Panel Review

This article was originally published in The Gray Sheet

Executive Summary

Biomet plans to evaluate its ceramic-on-ceramic hip prosthesis in a 100-patient clinical study that is scheduled for completion in mid-2002, company officials report.

You may also be interested in...



Sulzer Medica Debuts Metasul Metal-On-Metal Wear-Resistant Hip Joint

Roll-out of Sulzer Medica's Metasul metal-on-metal hip joint replacement technology Aug. 10 following recent FDA market clearance makes it "the first medical device company to launch the metal-on-metal technology for use in hip joint replacement surgery in the U.S.," Sulzer claims.

Implant Sciences Aims At Orthopedic, Brachytherapy, Stent Markets With IPO

Implant Sciences Corp., currently developing a method for embedding radioactivity into coronary stents in partnership with Guidant, is looking to raise $6-7 mil. in an initial public offering this spring, according to a prospectus filed Feb. 10 with the Securities and Exchange Commission.

Could Revisiting US Approval Decisions Become Less Rare?

While not identifying specific situations raising potential questions, the FDA commissioner uses his appearance at agency's annual rare disease event to advise regulatory decisions may be revisited as more data becomes available. 
UsernamePublicRestriction

Register

MT013590

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel